You Position: Home > Paper

The clinical efficacy and safety of transurthral electrovaporization of the prostate (TUVP) for benign prostatic hyperplasia( BPH) at high risk

( views:280, downloads:56 )
Author:
No author available
Journal Title:
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
Issue:
12
DOI:
10.3760/cma.j.issn.1008-6706.2011.12.009
Key Word:
前列腺增生;经尿道前列腺汽化电切除术;Prostatic hyperplasia;Transurethral electrovaporization of prostate

Abstract: Objective To investigate the clinical efficacy and safety of transurthral electrovaporization of the prostate(TUVP) for benign prostatic hyperplasia( BPH) at high risk.Methods Forty-eight patients with BPH at high risk were treated with transurthral electrovaporization of the prostate(TUVP).The clinical data and therapeutic results were measured.Results All patients went through the perioperiative period safely and had been followed up for 3 to 14 months.Postvoid residual ( PVR) , the International Prostate Symptom Score (IPSS) and quality of life (QOL) before operations were (97.5 ± 16.9) ml, ( 28.4 ± 2.3 ) score and (5.5 ±0.6) score respectively.Three months after operation ,PVR ,IPSS and QOL were( 30.2 ± 12.3 ) ml, (8.2 ± 1.3 ) score and( 1.9 ±0.5) score respectively,there was significant difference between them(t =22.31,53.16,31.94,all P<0.05).Conclusion TUVP is an effective and safe method in treating BPH patients at high risk.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn